Semaglutide and tirzepatide are peptide drugs, and so is nearly everything sold to you under the label “peptide therapy” for weight loss. That is where the similarity ends. One category has been through trials with thousands of participants and years of follow-up. The other category, AOD9604, CJC-1295, ipamorelin and the rest of the gray-market weight-loss peptide shelf, has almost nothing of the kind. This is not a both-sides comparison. It is a mismatch, and the size of the mismatch is the actual story.
Two evidence bases, not two flavors of the same thing
Tirzepatide is an engineered peptide built to activate both the GIP and GLP-1 receptors. In head-to-head data, it produced greater weight loss than the GLP-1 receptor agonist semaglutide.[1] Both drugs went through the same kind of trial program: thousands of participants, years of dosing, published results with confidence intervals attached.
Compounds like AOD9604 and the growth-hormone secretagogues CJC-1295 and ipamorelin did not go through that process. Some of them have small pharmacokinetic studies. None of them have what semaglutide and tirzepatide have.
Bottom line: if a compound is called a peptide, that tells you nothing about how well it is studied. Semaglutide, tirzepatide and CJC-1295 are all peptides. Only two of the three have been through a real outcome trial.
The distinction that matters for someone deciding what to do is whether a compound has been tested in an adequately powered human trial. Being called a peptide has nothing to do with it.
What the randomized trials show for semaglutide and tirzepatide
The two approved drugs share a research pedigree that nothing else in the peptide market comes close to.
Semaglutide. In a double-blind trial of 1,961 adults with obesity or overweight, 68 weeks of once-weekly semaglutide 2.4 mg produced a mean weight change of -14.9%, against -2.4% with placebo, a treatment difference of 12.4 percentage points.[2] More than two-thirds of the semaglutide group lost 10% or more of their body weight, versus 12% on placebo.
Tirzepatide. In a phase 3 trial of 2,539 adults, the 15 mg weekly dose of tirzepatide produced a mean weight change of -20.9% at 72 weeks, against -3.1% with placebo.[3] At the 10 mg and 15 mg doses, roughly half to more than half of participants lost 20% or more of their body weight. Three percent managed that on placebo.
-20.9%mean weight change with the highest tirzepatide dose vs -3.1% on placebo, at 72 weeksPMID 35658024
Both trials were multicenter, randomized, double-blind, placebo-controlled studies, the strongest available human study design for showing that the drug itself, not the diet counseling everyone also received, caused the weight loss.[2]
The catch: the effect does not appear to be permanent. In the STEP 1 extension, participants who lost a mean of 17.3% of body weight by week 68 regained 11.6 percentage points of it within a year of stopping the drug, netting out at a 5.6% loss from baseline at week 120.[4] Two-thirds of the weight came back. This is a chronic-disease drug with a chronic-dosing requirement; stop taking it and the underlying disease reasserts itself.
What the popular research peptides have instead
Here is where the comparison stops being close.
AOD9604, a fragment of human growth hormone, entered phase IIa obesity trials with its manufacturer, Metabolic Pharmaceuticals, by February 2002.[5] No peer-reviewed publication of what those trials found appears in the indexed literature. Twenty-plus years on, that is not a temporary gap. A compound with a positive obesity trial gets published, because a positive trial is worth a licensing deal. Silence this long is itself a data point.
CJC-1295, a long-acting growth-hormone-releasing hormone analog, has real human data, just not the kind that matters here. Two randomized, placebo-controlled trials in healthy adults showed dose-dependent increases in growth hormone (2- to 10-fold) and IGF-1 (1.5- to 3-fold) lasting six days or more after a single injection.[6] Nobody in that trial had their body weight or fat mass measured as an outcome.
Ipamorelin circulates in the same forums and stacks as CJC-1295, with pharmacokinetic data of its own but no published randomized trial measuring weight or fat mass either.
I could not find a study that isolates the growth hormone or IGF-1 signaling pathway these secretagogues are supposed to work through in animal or cell models specifically. That claim shows up constantly in marketing copy for these peptides. I cannot verify it against a citable source, so I am not going to repeat it as if it were established.
Recombinant human growth hormone itself had to clear large randomized trials in growth-hormone-deficient children and adults before regulators approved it for anything. CJC-1295 and ipamorelin have skipped that step. They have dose-response curves in healthy volunteers and nothing resembling an outcome trial in the population they are marketed to.
Receptor pharmacology versus an open question
GLP-1 receptor agonists work through a mechanism that has been characterized for decades: they slow gastric emptying, inhibit glucagon secretion, act on hypothalamic nuclei to enhance satiety, and promote glucose-mediated insulin release.[7] Large randomized trials built on that mechanism have also shown reduced cardiovascular risk and slower progression to kidney failure in high-risk patients, an effect nobody predicted from the weight-loss data alone.
Tirzepatide’s advantage over GLP-1-only drugs is usually explained as an added contribution from GIP receptor agonism. That explanation is less settled than it sounds. In a randomized crossover study of 17 overweight or obese men, GLP-1 infusion alone significantly reduced how much food participants ate at a subsequent meal. Adding GIP infusion on top of GLP-1 did not reduce intake any further, and GIP infusion alone did nothing.[8] So the acute human appetite data does not show GIP adding anything, even though tirzepatide’s clinical results are better than semaglutide’s. Something about GIP receptor agonism appears to matter for tirzepatide’s edge. What exactly, and through which pathway, is not resolved by the citation available here.
The growth-hormone secretagogue peptides don’t have this problem because they don’t have a receptor-pharmacology answer to lose an argument with. The physiological link between growth hormone and lipolysis has mostly been studied through short experiments in a different direction than the marketing claim runs: one trial found that pharmacologically blocking lipolysis in obese adults restored their blunted nocturnal growth hormone pulsatility, the opposite causal arrow from “GH pulses drive fat loss.”[9] That is a real, interesting physiological finding. It is not a fat-mass outcome trial for a growth-hormone-releasing peptide.
Dosing as published, not as sold
What the trials used:
Semaglutide: titrated from a starting dose up to 2.4 mg weekly over 16 weeks, a schedule built specifically to limit gastrointestinal side effects.[2]
Tirzepatide: a 20-week dose-escalation period leading to weekly maintenance doses of 5 mg, 10 mg or 15 mg.[3]
What circulates in online peptide communities for CJC-1295, ipamorelin and similar compounds comes from anecdotal protocols passed around forums and vendor sites. No published dose-ranging trial backs any of it. Nobody ran the equivalent of a large randomized dosing program to establish what dose of CJC-1295 does what, at what risk, over what timeframe. Call the dosing you’ll find online for these compounds what it is: folk pharmacology.
Side effects, red flags and what’s unknown
For semaglutide and tirzepatide, the adverse-event pattern is well characterized because it comes from trials designed to characterize it:
Pooled data from the semaglutide trials found gastrointestinal events, chiefly nausea, diarrhea and vomiting, were the most common side effects, occurring mostly during dose escalation.[10]
Tirzepatide’s adverse events followed the same gastrointestinal pattern, dose-related and mostly mild to moderate.[3]
The semaglutide class boxed warning about thyroid C-cell tumors traces back to rodent studies of a related GLP-1 receptor agonist, which found thyroid C-cell tumors in rats and mice but a species-specific mechanism: primates and humans have much lower GLP-1 receptor expression in thyroid C-cells, and the same rodent signal did not appear in monkeys dosed for 20 months or in two years of human calcitonin monitoring.[11] The researchers themselves concluded that the long-term human consequences remain unknown, which is a more honest summary than either “rodents got cancer, be afraid” or “it’s just a rodent thing, ignore the label.”
For CJC-1295, ipamorelin and AOD9604, there is no equivalent safety literature to summarize, because these compounds are typically sold as research chemicals outside FDA-regulated pharmaceutical manufacturing. Purity, dosing accuracy and contamination risk have not been systematically studied.
The real risk comparison: with semaglutide and tirzepatide, you are weighing a documented risk against a documented benefit. With CJC-1295, ipamorelin or AOD9604, you are weighing an undocumented risk against an unproven benefit. That is a worse trade than it sounds like.
What could change this comparison
The gap is not static. Retatrutide, a triple agonist at the GIP, GLP-1 and glucagon receptors, produced substantial weight loss in a phase 2 trial: at 48 weeks, the 12 mg dose produced a mean change of -24.2%, against -2.1% on placebo.[12] That’s a candidate earning its place through the same randomized evidence base that built the case for semaglutide and tirzepatide.
Mean body weight change at 48-72 weeks vs placebo
Semaglutide 2.4mg (68wk)-14.9
Tirzepatide 15mg (72wk)-20.9
Retatrutide 12mg (48wk)-24.2
Highest studied dose in each trial. Different trial lengths and populations; not a head-to-head comparison.
On the compounded and research-grade side, the pressure building right now is a policy fight, and it hasn’t produced any new trial data. The Obesity Medicine Association’s 2023 position statement on compounded peptides, followed by a 2024 FAQ it called a “call for action,” frames the compounded-peptide market largely as a symptom of drug shortages, high cost and unclear FDA guidance, and pushes drugmakers, compounding pharmacies, insurers and the FDA toward regulatory clarity.[13] That’s a different problem than the one CJC-1295 and ipamorelin have. Compounded semaglutide exists because approved semaglutide is expensive and sometimes unavailable. CJC-1295 exists because nobody ran the trial that would tell you whether it works.
If you want an evidence-based option in this category, semaglutide and tirzepatide are it, along with tesamorelin, a growth-hormone-releasing peptide that, unlike CJC-1295, has FDA approval and trial data behind a specific indication. If you’re evaluating a research peptide against that bar, check whether it has human trials at all before you check anything else about it.
The dose-response curve for these drugs keeps climbing. The evidence bar for the compounds around them has not moved.
Bottom line: semaglutide and tirzepatide earned their results in trials large enough to trust. CJC-1295, ipamorelin and AOD9604 are still waiting on the trial that would tell anyone whether they work at all.
This article is for research and informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. The peptides discussed here are sold for research use only and are not for human consumption. Nothing in this article constitutes medical advice. Consult a qualified clinician before making changes to a health, training, or supplementation protocol.
References
Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction.. Cardiovascular diabetology, 2022.
Once-Weekly Semaglutide in Adults with Overweight or Obesity.. The New England journal of medicine, 2021.
Tirzepatide Once Weekly for the Treatment of Obesity.. The New England journal of medicine, 2022.
Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.. Diabetes, obesity & metabolism, 2022.
AOD-9604 Metabolic.. Current opinion in investigational drugs (London, England : 2000), 2004.
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.. The Journal of clinical endocrinology and metabolism, 2006.
GLP-1 Receptor Agonists.. The New England journal of medicine, 2026.
Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study.. Diabetologia, 2019.
Acute pharmacologic blockade of lipolysis normalizes nocturnal growth hormone levels and pulsatility in obese subjects.. Metabolism: clinical and experimental, 1994.
Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss.. Diabetes, obesity & metabolism, 2022.
Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation.. Endocrinology, 2010.
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.. The New England journal of medicine, 2023.
Frequently asked questions to the 2023 obesity medicine association position statement on compounded peptides: A call for action.. Obesity pillars, 2024.
